Skip to search formSkip to main contentSkip to account menu

gemcitabine Injection [Gemzar]

National Institutes of Health

Related topics

Related topics

3 relations
GemzarInjection

Narrower (1)

gemcitabine 200 MG Injection [Gemzar]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract B127: NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders
Feedback activation of STAT3 and IGF1R/IRS plays a prominent role in mediating drug resistance to a broad spectrum of targeted… 
2018
2018
Abstract 2754: NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders
Feedback activation of STAT3 and IGF1R/IRS plays a prominent role in mediating drug resistance to a broad spectrum of targeted… 
2013
2013
Polymer therapeutics : A combinational drug delivery approach for effective cancer treatment
SUMMARY Non small cell lung cancer (NSCLC) has a grim prognosis even though there are advancements in its early diagnosis and… 
Review
2005
Review
2005
Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.
Keyowrds: adenocarcinoma, epidermal growth factor, nonsmall cell lung cancer, tyrosine kinase mutations Chemotherapy in lung… 
2004
2004
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine
Summary2′,2′-difluorodeoxycytidine (LY 188011, Gemcitabine, Gemzar®) has recently been approved both in Europe for the treatment… 
2003
2003
P-201 First-line chemotherapy with gemzar® (gemcitabine, GEM) and cisplatin (CIs) in Asian patients with advanced non-small cell lung cancer (NSCLC) — A prospective observational study
2002
2002
A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma
AbstractIntroduction: Recombinant humaninterferon-α2b (rHuIFN-α2b)and Interleukin-2 have limitedeffectiveness in the treatment… 
1999
1999
Gemzar® (G) and epirubicin (E) in patients (pts) with metastatic breast cancer (MBC): Final results of a phase I dose finding study
1997
1997
Gemcitabine in Solid Tumors – Present Status and Further Development
Gemcitabine [Gemzar®] is a nucloside analogue with clinical significant activity against different solid tumors. Currently… 
1997
1997
PP43. Quality of life assessments of patients with non-small cell lung cancer receiving gemcitabine (Gemzar™) and cisplatin
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)